Content about Medicine

October 24, 2010

The Food and Drug Administration has approved risk evaluation and mitigation strategies for two sleep...

FRAZER, Pa. The Food and Drug Administration has approved risk evaluation and mitigation strategies for two sleep disorder drugs made by Cephalon, the drug maker said.

 

Cephalon announced that the FDA approved the REMS for Nuvigil (armodafinil) and Provigil (modafinil), both used to improve wakefulness in patients with sleep apnea, narcolepsy or shift work disorder.

 

 

October 24, 2010

Independent pharmacies in 2009 generally were able to withstand the pummeling of a major recession,...

October 24, 2010

In recognition of American Diabetes Month in November, MinuteClinic is offering complimentary A1c tests beginning...

WOONSOCKET, R.I. In recognition of American Diabetes Month in November, MinuteClinic is offering complimentary A1c tests beginning Oct. 25 through Nov. 25, CVS Caremark has announced. The free tests, sponsored by Bayer Diabetes Care, are available while supplies last.

October 24, 2010

Identigene, the first company to bring at-home paternity test kits to retail, recently launched another...

Identigene, the first company to bring at-home paternity test kits to retail, recently launched another trailblazing at-home test kit: Identigene’s STD test.

October 24, 2010

Community pharmacists got a briefing about pharmacy security from a company that has learned a...

October 24, 2010

Kaz, the maker of Vicks, Honeywell and Braun wellness devices, recently launched a new Facebook...

October 24, 2010

Speculation has emerged that Eli Lilly may seek to acquire several other companies in light...

NEW YORK Speculation has emerged that Eli Lilly may seek to acquire several other companies in light of its difficulties winning approval for a long-acting diabetes treatment, according to published reports.

 

October 24, 2010

According to a recent study released by the Relational Capital Group, consumer purchase intent and...

PHILADELPHIA —According to a recent study released by the Relational Capital Group, consumer purchase intent and brand loyalty for Tylenol still is high despite the recent spate of Tylenol product recalls. According to the study, 76% of consumers reported positive purchase intent, and 67% reported positive brand loyalty for Tylenol.

October 24, 2010

Some say it cheapens patient care and reduces quality. The nation’s fourth-biggest pharmacy retailer and...

October 21, 2010

A few days after it released a report on how awareness and education play an...

PRINCETON, N.J. A few days after it released a report on how awareness and education play an integral role in the prevention, detection and treatment of diabetes, Novo Nordisk is bringing it to the public.

October 21, 2010

The rate of diabetes among Americans is on an upswing and likely will reach epic...

ATLANTA The rate of diabetes among Americans is on an upswing and likely will reach epic proportions by 2050, costing the government millions.

 

October 21, 2010

Diamyd Medical will split its business into separate divisions for pain relief and diabetes, the...

STOCKHOLM Diamyd Medical will split its business into separate divisions for pain relief and diabetes, the drug maker said Friday.

 

The Swedish company said its diabetes business would consist mostly of the investigational antigen-based drug Diamyd, for Type 1 diabetes, while the pain business would comprise of development projects using its nerve-targeting drug delivery system platform to administer drugs directly to the nervous system to treat pain.

 

 

October 21, 2010

The dramatic rise in the prevalence of diabetes over the next several decades is likely...

WHAT IT MEANS AND WHY IT'S IMPORTANT The dramatic rise in the prevalence of diabetes over the next several decades is likely to place huge strains on the U.S. healthcare system, costing the country hundreds of billions of dollars every year. It also means the diabetes market will continue to be a hot bed for innovation for decades to come.

(THE NEWS: Diabetes prevalence among Americans may increase to 33%, CDC study finds. For the full story, click here)

October 21, 2010

Sandoz has launched a generic antibiotic drug, the generics division of Swiss drug maker Novartis...

PRINCETON, N.J. Sandoz has launched a generic antibiotic drug, the generics division of Swiss drug maker Novartis said Thursday.

 

Sandoz announced the launch of piperacillin and tazobactam for injection. The drug is used to treat moderate to severe infections of bacteria resistant to piperacillin alone but vulnerable to the combination of the two drugs.

 

 

October 20, 2010

Combining two antiviral drugs for HIV may raise the risks of life-threatening heart problems, the...

October 20, 2010

The Food and Drug Administration has approved a biotech drug for treating cancer of the...

SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a biotech drug for treating cancer of the stomach and esophageal junction.

 

Genentech, a subsidiary of Swiss drug maker Roche, announced Wednesday the approval of Herceptin (trastuzumab) as a treatment for cancer of the stomach that includes the HER2 gene and has spread to other parts of the body, when combined with chemotherapy. The drug has long since had approval as a treatment for HER2-positive breast cancer.

 

 

October 20, 2010

The Food and Drug Administration has approved a Mylan generic drug for Parkinson’s disease, Mylan...

PITTSBURGH The Food and Drug Administration has approved a Mylan generic drug for Parkinson’s disease, Mylan said Thursday.

 

The drug maker announced the approval of pramipexole dihydrochloride tablets in the 0.125-mg, 0.25-mg, 0.5-mg, 1-mg and 1.5-mg strengths. The drug is a generic version of Boehringer Ingelheim’s Mirapex.

 

 

October 20, 2010

The Food and Drug Administration could decide that some generic drugs are not equivalent to...

BETHESDA, Md. The Food and Drug Administration could decide that some generic drugs are not equivalent to their branded counterparts, according to published reports.

 

October 20, 2010

In line with American Diabetes Month, one drug store chain is offering its diabetes patients...

October 20, 2010

A pharmacy that specializes in serving patients with chronic medical conditions has received accreditation status...

October 19, 2010

Patients taking a certain class of drugs mostly used for prostate cancer may be at...

SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.

 

October 19, 2010

The Food and Drug Administration approved a drug for preventing strokes and blood clots in...

SILVER SPRING, Md. The Food and Drug Administration approved a drug for preventing strokes and blood clots in patients with abnormal heart rhythm, the agency said Tuesday.

 

The FDA announced the approval of Pradaxa (dabigatran etexilate) capsules, an anticlotting drug made by Boehringer Ingelheim for patients with atrial fibrillation, a type of abnormal heart rhythm that affects more than 2 million Americans.

 

 

October 19, 2010

The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli...

INDIANAPOLIS The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli Lilly and two other companies, the companies said Tuesday.

Lilly, Amylin Pharmaceuticals and Alkermes said the FDA issued them a complete response letter for their application for Bydureon (exenatide), a once-weekly version of the Type 2 diabetes drug Byetta. A complete response letter means that the FDA has completed review of a regulatory application, but issues remain that preclude approval.

 

October 19, 2010

Americans can lower their total medical costs significantly by taking simple steps to prevent or...

BLOOMFIELD, Conn. Americans can lower their total medical costs significantly by taking simple steps to prevent or manage disease and by switching to generic drugs whenever possible, new research from health insurance giant Cigna confirmed.

October 19, 2010

Clinical skin care brand Kinerase, which has a long history of creating high-end skin care...

ALISO VIEJO, Calif. Clinical skin care brand Kinerase, which has a long history of creating high-end skin care products for both the physician and prestige channels, now has developed a new line for the mass market -- Dr. LeWinn by Kinerase.

Dr. LeWinn by Kinerase, a new hybrid of skin care products for consumers who need a more accessible price point, is comprised of 10 cleansers, moisturizers and daily treatments. The products will be available beginning February 2011 at select Walgreens and Walmart locations, and will retail for between $10 and $35.